Product Center
Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-14
- Views:
(Summary description) Recently, the Science and Technology Bureau of Taizhou City announced the first batch of offshore innovation centers for enterprises, and Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） wholly-owned subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) Successfully obtained recognition.
Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou
(Summary description) Recently, the Science and Technology Bureau of Taizhou City announced the first batch of offshore innovation centers for enterprises, and Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） wholly-owned subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) Successfully obtained recognition.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-08-14 18:02
- Views:
Recently, the Science and Technology Bureau of Taizhou City announced the first batch of offshore innovation centers for enterprises, and Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）wholly-owned subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) Successfully obtained recognition.
Since its establishment, Yihui Biotechnology has jointly established a collaborative innovation model of "offshore research and development incubation, local transformation and application" with Zhonghui Biotechnology, leveraging advanced regional innovative resources to carry out key core technology research and development. As of now, two clinical approvals for Class I new drugs have been successfully jointly applied for and approved.
Next, the company will also actively promote the two-way linkage between local innovation and offshore innovation, strengthen the exchange, interaction and circulation of talents, cultivate a batch of scientific and technological innovation achievements, and continue to complete the implementation and application of innovation achievements, so as to help the high-quality development of the city's biomedical industry!
Relevant information
-
The application for the marketing of trivalent influenza virus subunit vaccine has been accepted!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）has received acceptance from the Drug Evaluation Center (CDE) of the China National Medical Products Administration for its application to market the "6-35 month old trivalent influenza virus subunit vaccine" and the "3-year-old and above trivalent influenza virus subunit vaccine". This acceptance marks the final sprint stage of the first domestic full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched! - Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
